Download PDF
Transfusionsmedizin 2015; 5(1): 31-43
DOI: 10.1055/s-0033-1358086
CME-Fortbildung
Georg Thieme Verlag KG Stuttgart · New York

Rationale Flüssigkeits- und Volumentherapie – eine kritische Betrachtung unter Berücksichtigung aktueller Empfehlungen und Leitlinien

M. Heringlake
Klinik für Anästhesiologie und Intensivmedizin, Universität zu Lübeck
,
H. Heinze
Klinik für Anästhesiologie und Intensivmedizin, Universität zu Lübeck
,
K. Brauer
Klinik für Anästhesiologie und Intensivmedizin, Universität zu Lübeck
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Trotz aktueller Leitlinienempfehlungen kann die Diskussion über den Stellenwert kristalliner, synthetischer und natürlicher kolloidaler Infusionslösungen im Rahmen perioperativer und intensivmedizinischer Therapie keineswegs als abgeschlossen betrachtet werden.

So fehlen nicht nur klare Daten zur Sicherheit einer rein kristallinen Volumentherapie und zum Einsatz künstlicher Kolloide bei operativen Risikopatienten, es stellt sich ebenfalls zunehmend die Frage, ob kritisch kranke Intensivpatienten und insbesondere Patienten im septischen Schock – entgegen gegenwärtigen Empfehlungen – nicht doch von einer mit Humanalbumin ergänzten Volumentherapie profitieren.

Zielsetzung der vorliegenden Arbeit ist es, das Für und Wider beim Einsatz der verschiedenen Infusionslösungen zur Volumentherapie unter Berücksichtigung physiologischer und pathophysiologischer Aspekte und vor dem Hintergrund aktueller Studien und Empfehlungen kritisch zu beleuchten.

Schlüsselwörter

Volumentherapie - Volumenersatzmittel - kristallin - kolloidal - Hydroxyethylstärke - Gelatine - Humanalbumin - akutes Nierenversagen
 

  • Literatur

  • 1 Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin. S3-Leitlinie: Intravasale Volumentherapie beim Erwachsenen (31.07.2014). Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/001-020l_S3_Intravasale_Volumentherapie_Erwachsenen_2014-09.pdf Stand: 14.1.2015
    PubMedGoogle Scholar
  • 2 Bundesärztekammer. Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten (2014). Im Internet: http://www.bundesaerztekammer.de/downloads/QLL_Haemotherapie_2014.pdf Stand: 14.1.2015
    PubMedGoogle Scholar
  • 3 Kellum JA, Song M, Venkataraman R. Effects of hyperchloremic acidosis on arterial pressure and circulating inflammatory molecules in experimental sepsis. Chest 2004; 125: 243-248
    Google Scholar
  • 4 Shaw AD, Bagshaw SM, Goldstein SL et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9 % saline compared to Plasma-Lyte. Ann Surg 2012; 255: 821-829
    CrossrefPubMedGoogle Scholar
  • 5 Raghunathan K, Shaw A, Nathanson B et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med 2014; 42: 1585-1591
    CrossrefPubMedGoogle Scholar
  • 6 Krajewski ML, Raghunathan K, Paluszkiewicz SM et al. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. Br J Surg 2015; 102: 24-36
    CrossrefPubMedGoogle Scholar
  • 7 McCluskey SA, Karkouti K, Wijeysundera D et al. Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study. Anesth Analg 2013; 117: 412-421
    Google Scholar
  • 8 Yunos NM, Bellomo R, Hegarty C et al. Association between a chloride-liberal vs. chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012; 308: 1566-1572
    CrossrefPubMedGoogle Scholar
  • 9 Van Aken H, Jacob M, Westphal M et al. Infusionstherapie in der Anästhesiologie und Intensivmedizin: Gestern, heute und morgen. Anästh Intensivmed 2009; 50: 338-345
    PubMedGoogle Scholar
  • 10 Jacob M, Chappell D. Mythen und Fakten der perioperativen Infusionstherapie. Anästh Intensivmed 2009; 50: 358-376
    PubMedGoogle Scholar
  • 11 Jacob M, Chappell D, Hollmann MW. Current aspects of perioperative fluid handling in vascular surgery. Curr Opin Anaesthesiol 2009; 22: 100-108
    CrossrefPubMedGoogle Scholar
  • 12 Jacob M, Chappell D, Hofmann-Kiefer K et al. The intravascular volume effect of Ringerʼs lactate is below 20 %: a prospective study in humans. Crit Care 2012; 16: R86
    CrossrefPubMedGoogle Scholar
  • 13 Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; (2) CD000567
    PubMedGoogle Scholar
  • 14 Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-139
    CrossrefPubMedGoogle Scholar
  • 15 Perner A, Haase N, Guttormsen AB et al. Hydroxyethyl starch 130/0.42 versus Ringerʼs acetate in severe sepsis. N Engl J Med 2012; 367: 124-134
    CrossrefPubMedGoogle Scholar
  • 16 Guidet B, Martinet O, Boulain T et al. Assessment of hemodynamic efficacy and safety of 6 % hydroxyethylstarch 130/0.4 vs. 0.9 % NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care 2012; 16: R94
    CrossrefPubMedGoogle Scholar
  • 17 Myburgh JA, Finfer S, Bellomo R et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367: 1901-1911
    CrossrefPubMedGoogle Scholar
  • 18 Annane D, Siami S, Jaber S et al. Effects of fluid resuscitation with colloids vs. crystalloids on mortality in critically ill patients presenting with hypovolemic shock: the CRISTAL randomized trial. JAMA 2013; 310: 1809-1817
    CrossrefPubMedGoogle Scholar
  • 19 Martin C, Jacob M, Vicaut E et al. Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 2013; 118: 387-394
    CrossrefPubMedGoogle Scholar
  • 20 Gillies MA, Habicher M, Jhanji S et al. Incidence of postoperative death and acute kidney injury associated with i.v. 6 % hydroxyethyl starch use: systematic review and meta-analysis. Br J Anaesth 2014; 112: 25-34
    CrossrefPubMedGoogle Scholar
  • 21 Barron ME, Wilkes MM, Navickis RJ. A systematic review of the comparative safety of colloids. Arch Surg 2004; 139: 552-563
    CrossrefPubMedGoogle Scholar
  • 22 Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007; 94: 427-433
    CrossrefPubMedGoogle Scholar
  • 23 Department of Health and Human Services: Food and Drug Administration, 21 CFR Part 216 [Docket No. 98 N-0655] list of drug products that have been withdrawn or removed from the market for reasons of safety or effectiveness. Federal Register (Volume 64), 1999; Volume 4, 10947. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm155421.pdf Stand: 14.1.2015
    Google Scholar
  • 24 Bayer O, Reinhart K, Kohl M et al. Effects of fluid resuscitation with synthetic colloids or crystalloids alone on shock reversal, fluid balance, and patient outcomes in patients with severe sepsis: a prospective sequential analysis. Crit Care Med 2012; 40: 2543-2551
    CrossrefPubMedGoogle Scholar
  • 25 Bayer O, Schwarzkopf D, Doenst T et al. Perioperative fluid therapy with tetrastarch and gelatin in cardiac surgery – a prospective sequential analysis. Crit Care Med 2013; 41: 2532-2542
    CrossrefPubMedGoogle Scholar
  • 26 Thomas-Rueddel DO, Vlasakov V, Reinhart K et al. Safety of gelatin for volume resuscitation – a systematic review and meta-analysis. Intensive Care Med 2012; 38: 1134-1142
    CrossrefPubMedGoogle Scholar
  • 27 Schick MA, Isbary TJ, Schlegel N et al. The impact of crystalloid and colloid infusion on the kidney in rodent sepsis. Intensive Care Med 2010; 36 (3) 541-548
    CrossrefPubMedGoogle Scholar
  • 28 Saw MM, Chandler B, Ho KM. Benefits and risks of using gelatin solution as a plasma expander for perioperative and critically ill patients: a meta-analysis. Anaesth Intensive Care 2012; 40: 17-32
    CrossrefPubMedGoogle Scholar
  • 29 Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998; 317 (7153) 235-240
    CrossrefPubMedGoogle Scholar
  • 30 Horsey P. Albumin and hypovolaemia: is the Cochrane evidence to be trusted. Lancet 2002; 359 (9300) 70-72
    CrossrefPubMedGoogle Scholar
  • 31 Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol 2014; 5: 299
    PubMedGoogle Scholar
  • 32 Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-2256
    CrossrefPubMedGoogle Scholar
  • 33 Cooper DJ, Myburgh J, Heritier S et al. Albumin resuscitation for traumatic brain injury: is intracranial hypertension the cause of increased mortality?. J Neurotrauma 2013; 30: 512-518
    CrossrefPubMedGoogle Scholar
  • 34 Finfer S, McEvoy S, Bellomo R et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med 2011; 37: 86-96
    CrossrefPubMedGoogle Scholar
  • 35 Charpentier J, Mira J-P. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: the EARSS study. Intensive Care Med 2011; 37 (Suppl. 01) 115
    PubMedGoogle Scholar
  • 36 Caironi P, Tognoni G, Masson S et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370: 1412-1421
    CrossrefPubMedGoogle Scholar
  • 37 Rochwerg B, Alhazzani W, Sindi A et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 2014; 161: 347-355
    CrossrefPubMedGoogle Scholar
  • 38 Wiedermann CJ, Joannidis M. Albumin replacement in severe sepsis or septic shock. N Engl J Med 2014; 371: 83
    CrossrefPubMedGoogle Scholar
  • 39 Delaney AP, Dan A, McCaffrey J et al. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011; 39: 386-391
    CrossrefPubMedGoogle Scholar
  • 40 Groeneveld AB, Navickis RJ, Wilkes MM. Update on the comparative safety of colloids: a systematic review of clinical studies. Ann Surg 2011; 253: 470-483
    CrossrefPubMedGoogle Scholar
  • 41 Vincent JL, Navickis RJ, Wilkes MM. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 2004; 32: 2029-2038
    CrossrefPubMedGoogle Scholar
  • 42 Patel A, Laffan MA, Waheed U et al. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ 2014; 349: 4561
    CrossrefPubMedGoogle Scholar
  • 43 Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637
    CrossrefPubMedGoogle Scholar
  • 44 Reinhart K, Perner A, Sprung CL et al. Consensus statement of the ESICM task force on colloid volume therapy in critically patients. Intensive Care Med 2012; 38: 368-383
    CrossrefPubMedGoogle Scholar
  • 45 Roberts I, Blackhall K, Alderson P et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2011; (11) CD001208
    PubMedGoogle Scholar
  • 46 Schortgen F, Girou E, Deye N et al. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008; 34: 2157-2168
    CrossrefPubMedGoogle Scholar
  • 47 Wiedermann CJ, Dunzendorfer S, Gaioni LU et al. Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. Crit Care 2010; 14: R191
    CrossrefPubMedGoogle Scholar
  • 48 Cerda J, Sheinfeld G, Ronco C. Fluid overload in critically ill patients with acute kidney injury. Blood Purif 2010; 29: 331-338
    CrossrefPubMedGoogle Scholar